tiprankstipranks
New Urothelial Cancer Treatment Approved in China
Company Announcements

New Urothelial Cancer Treatment Approved in China

Astellas Pharma (JP:4503) has released an update.

Don't Miss our Black Friday Offers:

Astellas Pharma has announced that China’s National Medical Products Administration has approved PADCEVTM for the treatment of locally advanced or metastatic urothelial cancer following prior platinum-based chemotherapy and PD-1/L1 inhibitors. The approval is supported by the positive results from the global EV-301 trial and the China EV-203 trials, showing significant improvements in overall survival and objective response rates. This marks an important development in providing new treatment options for patients suffering from this aggressive form of cancer in China.

For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Japan Auto-Generated NewsdeskAstellas Faces FDA Setback on IZERVAY Application
TipRanks Japan Auto-Generated NewsdeskAstellas Pharma Faces Currency Losses in FY2024
Austin AngeloALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App